Treatment with the vascular disrupting agent combretastatin is associated with impaired AQP2 trafficking and increased urine output

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 303, Issue 2, 2012, Pages

  Bohn, Anja B ^a   Nørregaard, Rikke ^b   Stødkilde, Lene ^b   Wang, Yan ^b   Bertelsen, Lotte B ^a   Fenton, Robert A ^b   Matchkov, Vladimir V ^b   Bouzinova, Elena V ^b   Horsman, Michael R ^a   Frøkiaer, Jørgen ^b   Stødkilde Jørgensen, Hans ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

AQP2 localization; Hemoglobin; Rats; Renal function

Indexed keywords

AQUAPORIN 2; CARRIER PROTEIN; COMBRETASTATIN A4 PHOSPHATE; CYCLIC AMP; HEMOGLOBIN; MESSENGER RNA; VASOPRESSIN V2 RECEPTOR; AQP2 PROTEIN, RAT; BIBENZYL DERIVATIVE; COMBRETASTATIN; TUBULIN MODULATOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CELL MIGRATION; CONTROLLED STUDY; CYTOSKELETON; FLUID BALANCE; KIDNEY COLLECTING TUBULE; KIDNEY CORTEX; KIDNEY MEDULLA; KIDNEY PARENCHYMA; KIDNEY TUBULE CELL; MALE; MEAN ARTERIAL PRESSURE; MICROTUBULE; MUSCLE TISSUE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RAT; RENAL INNER MEDULLA; SODIUM BALANCE; SODIUM EXCRETION; SODIUM TRANSPORT; TISSUE WATER; URINE OSMOLALITY; URINE VOLUME; ANIMAL; ANIMAL MODEL; BLOOD PRESSURE; BRAIN; DRUG EFFECT; KIDNEY; METABOLISM; MICTURITION; PATHOLOGY; PHYSIOLOGY; PROTEIN TRANSPORT; SKELETAL MUSCLE; WISTAR RAT;

ANIMALS; AQUAPORIN 2; BIBENZYLS; BLOOD PRESSURE; BRAIN; CYTOSKELETON; HEMOGLOBINS; KIDNEY; MAGNETIC RESONANCE IMAGING; MALE; MODELS, ANIMAL; MUSCLE, SKELETAL; PROTEIN TRANSPORT; RATS; RATS, WISTAR; TUBULIN MODULATORS; URINATION;

EID: 84863953444     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00572.2011     Document Type: Article

References (48)

1. Banerjee S, Wang Z, Mohammad M, Sarkar FH, Mohammad RM. Efficacy of selected natural products as therapeutic agents against cancer. J Nat Prod 71: 492-496, 2008.
2. Boscan P, Pypendop BH, Siao KT, Francey T, Dowers K, Cowgill L, Ilkiw JE. Fluid balance, glomerular filtration rate, and urine output in dogs anesthetized for an orthopedic surgical procedure. Am J Vet Res 71: 501-507, 2010.
3. Brooks AC, Kanthou C, Cook IH, Tozer GM, Barber PR, Vojnovic B, Nash GB, Parkins CS. The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitro. Anticancer Res 23: 3199-3206, 2003.
4. Busk M, Bohn AB, Skals M, Wang T, Horsman MR. Combretastatininduced hypertension and the consequences for its combination with other therapies. Vascul Pharmacol 54: 13-17, 2011.
5. 2-receptor agonist/antagonist treatment. Am J Physiol Renal Physiol 278: F29-F42, 2000.
6. Cooney MM, Radivoyevitch T, Dowlati A, Overmoyer B, Levitan N, Robertson K, Levine SL, DeCaro K, Buchter C, Taylor A, Stambler BS, Remick SC. Cardiovascular safety profile of combretastatin A4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 10: 96-100, 2004.
7. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57: 1829-1834, 1997.
8. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin JS, McCrae KR, Remick SC. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62: 3408-3416, 2002.
9. Fatouros PP, Marmarou A. Use of magnetic resonance imaging for in vivo measurements of water content in human brain: method and normal values. J Neurosurg 90: 109-115, 1999.
10. Fatouros PP, Marmarou A, Kraft KA, Inao S, Schwarz FP. In vivo brain water determination by T1 measurements: effect of total water content, hydration fraction, and field strength. Magn Reson Med 17: 402-413, 1991.
11. Fenton RA, Chou CL, Stewart GS, Smith CP, Knepper MA. Urinary concentrating defect in mice with selective deletion of phloretin-sensitive urea transporters in the renal collecting duct. Proc Natl Acad Sci USA 101: 7469-7474, 2004.
12. Fushimi K, Sasaki S, Marumo F. Phosphorylation of serine 256 is required for cAMP-dependent regulatory exocytosis of the aquaporin-2 water channel. J Biol Chem 272: 14800-14804, 1997.
13. Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, Stirling JJ, Sena L, Padhani AR, Rustin GJ. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 21: 2831-2842, 2003.
14. Hasler U. Controlled aquaporin-2 expression in the hypertonic environment. Am J Physiol Cell Physiol 296: C641-C653, 2009.
15. Hasler U, Mordasini D, Bens M, Bianchi M, Cluzeaud F, Rousselot M, Vandewalle A, Feraille E, Martin PY. Long-term regulation of aquaporin-2 expression in vasopressin-responsive renal collecting duct principal cells. J Biol Chem 277: 10379-10386, 2002.
16. Henn V, Edemir B, Stefan E, Wiesner B, Lorenz D, Theilig F, Schmitt R, Vossebein L, Tamma G, Beyermann M, Krause E, Herberg FW, Valenti G, Bachmann S, Rosenthal W, Klussmann E. Identification of a novel A-kinase anchoring protein 18 isoform and evidence for its role in the vasopressin-induced aquaporin-2 shuttle in renal principal cells. J Biol Chem 279: 26654-26665, 2004.
17. Horsman MR, Murata R. Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys 57: 1047-1055, 2003.
18. Horsman MR, Siemann DW. Pathophysiologic effects of vasculartargeting agents and the implications for combination with conventional therapies. Cancer Res 66: 11520-11539, 2006.
19. Hozawa S, Holtzman EJ, Ausiello DA. cAMP motifs regulating transcription in the aquaporin 2 gene. Am J Physiol Cell Physiol 270: C1695-C1702, 1996.
20. Kanthou C, Tozer GM. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 99: 2060-2069, 2002.
21. Katsura T, Gustafson CE, Ausiello DA, Brown D. Protein kinase A phosphorylation is involved in regulated exocytosis of aquaporin-2 in transfected LLC-PK1 cells. Am J Physiol Renal Physiol 272: F817-F822, 1997.
22. Klussmann E, Tamma G, Lorenz D, Wiesner B, Maric K, Hofmann F, Aktories K, Valenti G, Rosenthal W. An inhibitory role of Rho in the vasopressin-mediated translocation of aquaporin-2 into cell membranes of renal principal cells. J Biol Chem 276: 20451-20457, 2001.
23. Knepper MA, Wade JB, Terris J, Ecelbarger CA, Marples D, Mandon B, Chou CL, Kishore BK, Nielsen S. Renal aquaporins. Kidney Int 49: 1712-1717, 1996.
24. Matsumura Y, Uchida S, Rai T, Sasaki S, Marumo F. Transcriptional regulation of aquaporin-2 water channel gene by cAMP. J Am Soc Nephrol 8: 861-867, 1997.
25. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 14: 2534-2543, 2003.
26. Moeller HB, Knepper MA, Fenton RA. Serine 269 phosphorylated aquaporin-2 is targeted to the apical membrane of collecting duct principal cells. Kidney Int 75: 295-303, 2009.
27. Murata R, Siemann DW, Overgaard J, Horsman MR. Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiat Res 156: 503-509, 2001.
28. Murata R, Siemann DW, Overgaard J, Horsman MR. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol 60: 155-161, 2001.
29. Nielsen J, Kwon TH, Praetorius J, Frokiaer J, Knepper MA, Nielsen S. Aldosterone increases urine production and decreases apical AQP2 expression in rats with diabetes insipidus. Am J Physiol Renal Physiol 290: F438-F449, 2006.
30. Nielsen S, Chou CL, Marples D, Christensen EI, Kishore BK, Knepper MA. Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proc Natl Acad Sci USA 92: 1013-1017, 1995.
31. Nielsen S, Frokiaer J, Marples D, Kwon TH, Agre P, Knepper MA. Aquaporins in the kidney: from molecules to medicine. Physiol Rev 82: 205-244, 2002.
32. Nielsen S, Kwon TH, Frokiaer J, Agre P. Regulation and dysregulation of aquaporins in water balance disorders. J Intern Med 261: 53-64, 2007.
33. Noda Y, Sohara E, Ohta E, Sasaki S. Aquaporins in kidney pathophysiology. Nat Rev Nephrol 6: 168-178, 2010.
34. Norregaard R, Jensen BL, Li C, Wang W, Knepper MA, Nielsen S, FrokiAEr J. COX-2 inhibition prevents downregulation of key renal water and sodium transport proteins in response to bilateral ureteral obstruction. Am J Physiol Renal Physiol 289: F322-F333, 2005.
35. Prise VE, Honess DJ, Stratford MR, Wilson J, Tozer GM. The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int J Oncol 21: 717-726, 2002.
36. Ridley AJ, Hall A. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70: 389-399, 1992.
37. Schmidt-Nielsen B, Graves B, Roth J. Water removal and solute additions determining increases in renal medullary osmolality. Am J Physiol Renal Fluid Electrolyte Physiol 244: F472-F482, 1983.
38. Shimogai M, Ogawa K, Tokinaga Y, Yamazaki A, Hatano Y. The cellular mechanisms underlying the inhibitory effects of isoflurane and sevoflurane on arginine vasopressin-induced vasoconstriction. J Anesth 24: 893-900, 2010.
39. Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MR, Marme D, Lorusso PM. Differentiation and definition of vasculartargeted therapies. Clin Cancer Res 11: 416-420, 2005.
40. Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, Giantonio B, Zimmer R, Petros WP, Stratford M, Chaplin D, Young SL, Schnall M, O'Dwyer PJ. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 21: 4428-4438, 2003.
41. Stodkilde L, Norregaard R, Fenton RA, Wang G, Knepper MA, Frokiaer J. Bilateral ureteral obstruction induces early downregulation and redistribution of AQP2 and phosphorylated AQP2. Am J Physiol Renal Physiol 2011.
42. Taylor A, Maffly R, Wilson L, Reaven E. Evidence for involvement of microtubules in the action of vasopressin. Ann NY Acad Sci 253: 723-737, 1975.
43. Tozer GM, Kanthou C, Parkins CS, Hill SA. The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol 83: 21-38, 2002.
44. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, Dennis MF, Chaplin DJ. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 59: 1626-1634, 1999.
45. Valenti G, Hugon JS, Bourguet J. To what extent is microtubular network involved in antidiuretic response? Am J Physiol Renal Fluid Electrolyte Physiol 255: F1098-F1106, 1988.
46. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49: 6449-6465, 1989.
47. Yasui M, Zelenin SM, Celsi G, Aperia A. Adenylate cyclase-coupled vasopressin receptor activates AQP2 promoter via a dual effect on CRE and AP1 elements. Am J Physiol Renal Fluid Electrolyte Physiol 272: F443-F450, 1997.
48. Zhao D, Jiang L, Hahn EW, Mason RP. Tumor physiologic response to combretastatin A4 phosphate assessed by MRI. Int J Radiat Oncol Biol Phys 62: 872-880, 2005.